Your Contact Sample Clauses

Your Contact. News Release Xxxxxxx Xxxxxx Phone +0-000-000-0000 March 30, 2015 Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy • Chimeric Antigen Receptor T-cell (CAR-T) therapy enhances Merck Serono’s R&D technology portfolio in immuno-oncology • Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates Darmstadt, Germany, March 30, 2015 – Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation (NYSE:XON), today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono’s comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system’s natural ability to fight tumors. “The collaboration with Intrexon underlies Merck Serono’s focus on innovation, and enhances its R&D technology portfolio in immuno-oncology,” says Xxxxx Xxxxxx, President and CEO of Merck Serono. “Moreover, it showcases Merck Serono’s commitment to developing therapies that have the potential to significantly evolve the way cancer is treated.” CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, an immunological attack against the cancer cells is triggered. Utilizing Intrexon’s cell engineering techniques and RheoSwitch® platform, the collaboration aims to develop leading-edge products that empower the immune system in a regulated manner to overcome the current challenges of CAR-T therapy. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. The agreement provides Merck Serono exclusive access to Intrexon’s proprietary and complementary suite of technologies to engineer T cells with optimized and inducible gene expression, as recently strengthened by a license agreement with the University of Texas MD Xxxxxxxx Cancer Center. Intrexon will be responsible for all platform and product developments until IND filing. Merck will nominate targets of interest for which CAR-T products will be developed. Merck will also lead the IND filing and pre-IND intera...
Sample 1Sample 2Sample 3See All (7)
AutoNDA by SimpleDocs
Your Contact. You will designate an individual who will have the responsibility to, and the authority of You, to make decisions concerning all matters relating to this Agreement (“Primary Contact”). You may change the individual designated as Primary Contact at any time by updating the information in the administration console for the Services.
Sample 1Sample 2Sample 3
Your Contact. You must designate a contact person (“Your Contact”) with whom Vital-Sim will communicate in relation to Support. You must notify Vital-Sim of the contact details, and any changes to those contact details, for Your Contract including telephone and facsimile numbers and email addresses. You may change Your Contact at any time by giving Vital-Sim reasonable notice of such change. Your Contact must be trained in the use of the Software, familiar with the Documentation and devote any necessary time and effort to assist Vital-Sim in resolving Problems in accordance with this Agreement. You will be solely responsible for any costs or expenses You incur in performing Your obligations under this Agreement, including the cost of any telecommunications or internet access charges. Contacting Vital-Sim Your Contact can contact Vital-Sim by: telephoning 000-000-0000; sending an email to support@vital-sim; or using the support that may be available on Vital-Sim’s website. Excluded Services Support does not include: installation, training, configuration, customization or other services not expressly described in Section 0; help with any Problem caused by: Your use of the Licensed Materials other than in accordance with this Agreement; modifications or alterations to the Licensed Materials not made by Vital-Sim; use of the Licensed Materials in connection or combination with equipment, devices or software that are not specified in writing by Vital-Sim as being compatible with the Software; Your failure to implement any Patches or Updates that are made available to You or; Your failure to implement any New Release of the Software, if Vital-Sim has given You at least 180 days’ notice that it will no longer be supporting previous releases of the Software; or any Support provided by Vital-Sim, at Your request, which is outside Business Hours or at Your facilities, (together the “Excluded Services”). Vital-Sim may, but is under no obligation to, perform such Excluded Services for You upon receipt of a request to do so. Fees and Taxes
Sample 1
Your Contact. Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name FINAL ENTRY TO BE RETURNED BEFORE 6 JUNE 2022 COUNTRY
Sample 1
Your Contact. Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name LATE REPLACEMENT FORM (LRF) TO BE SENT BY E-MAIL AFTER 6 JUNE 2022 AND BEFORE 20 JULY 2022 COUNTRY REPLACED MEMBER REPLACEMENT Rank Family Name Given Name Sport/ Function Rank Family Name Given Name Passport No. Your Contact Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name LATE REPLACEMENT FORM (LRF) AFTER 6 JUNE 2022 AND BEFORE 20 JULY 2022 COUNTRY FLIGHT AND TRAVEL INFORMATION DETAIL (Number of people per sport / city overview) FINAL DESTINATION ARRIVAL DEPARTURE FLIGHT (TRAIN) No. DATE TIME No. OF PEOPLE FLIGHT (TRAIN) No. DATE TIME No. OF PEOPLE Your Contact Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name 1Each Nation must bring 2 international referees for Volleyball Competitions (1 for Men and 1 for Women competition)
Sample 1

Related to Your Contact

  • Contact a. In accordance with section 215.971(2), Florida Statutes, the Division’s Grant Manager shall be responsible for enforcing performance of this Agreement’s terms and conditions and shall serve as the Division’s liaison with the Sub-Recipient. As part of his/her duties, the Grant Manager for the Division shall: payment.

  • PLEASE READ YOUR CONTRACT CAREFULLY It is a legal Contract between you, the Owner, and us, SBL. The Contract's table of contents is on page 2. FREE LOOK PERIOD-RIGHT TO CANCEL YOU MAY RETURN THIS CONTRACT WITHIN 10 DAYS AFTER YOU RECEIVE IT. YOU MAY RETURN THE CONTRACT BY DELIVERING OR MAILING IT TO SBL. THIS CONTRACT WILL THEN BE DEEMED VOID FROM THE BEGINNING. NO WITHDRAWAL CHARGE WILL BE IMPOSED, AND WE WILL REFUND YOUR CONTRACT VALUE, INCLUDING ANY FEES AND/OR CHARGES FOR PREMIUM TAX THAT WERE DEDUCTED FROM THAT CONTRACT VALUE, LESS THE VALUE OF ANY CREDIT ENHANCEMENTS MADE INTO THE CONTRACT, AS OF THE DATE WE RECEIVE THE RETURNED CONTRACT. Signed for Security Benefit Life Insurance Company on the Contract Date. XXXXX X. XXXXX XXXX X. XXXXXXX Secretary President A BRIEF DESCRIPTION OF THIS CONTRACT This is a FLEXIBLE PREMIUM DEFERRED VARIABLE ANNUITY CONTRACT. * Investment Experience is Reflected in Benefits * Variable and Fixed Accumulation Before the Annuity Start Date; Variable and Fixed Annuity Payments Thereafter * Death Benefit Proceeds are Payable Before the Annuity Start Date * This Contract is Non-Participating BENEFITS AND VALUES PROVIDED BY THIS CONTRACT MAY BE ON A VARIABLE BASIS. AMOUNTS DIRECTED INTO ONE OR MORE OF THE SUBACCOUNTS WILL REFLECT THE INVESTMENT EXPERIENCE OF THOSE SUBACCOUNTS. THESE AMOUNTS MAY INCREASE OR DECREASE AND ARE NOT GUARANTEED AS TO DOLLAR AMOUNT. (SEE "CONTRACT VALUE AND EXPENSE PROVISIONS" AND "ANNUITY PAYMENT PROVISIONS" FOR DETAILS.) [SBL LOGO] SECURITY BENEFIT LIFE INSURANCE COMPANY A Member of The Security Benefit Group of Companies 000 XX Xxxxxxxx Street, Topeka, KS 66636-0001 0-000-000-0000 The variable annuity covered by this Contract is the subject of a pending patent application in the United States Patent and Trademark Office. V6029 (8-00) -------------------------------------------------------------------------------- TABLE OF CONTENTS -------------------------------------------------------------------------------- Page CONTRACT DATA PAGE........................................................ 3 DEFINITIONS............................................................... 4

  • Relationship Management LAUSD expects Contractors and their Representatives to ensure that their business dealings with and/or on behalf of LAUSD are conducted in a manner that is above reproach.

  • Relationship Managers The Participant Relationship Manager and the Reclaim Fund Relationship Manager at the date of this agreement for the purposes of clause 27 of Part B of this agreement are as follows:

  • Contact details (a) Except as provided below, the contact details of each Party for all communications in connection with the Finance Documents are those notified by that Party for this purpose to the Facility Agent on or before the date it becomes a Party.

  • Contacts 1. Florida Housing’s contract administrator for this Agreement is: Contract Administrator Florida Housing Finance Corporation 000 Xxxxx Xxxxxxxx Xx., Xxxxx 0000 Xxxxxxxxxxx, Xxxxxxx 00000-0000 Phone: 000.000.0000 E-mail: Xxxxxxxx.Xxxxx@xxxxxxxxxxxxxx.xxx

  • Contact Person person who provides a link for administrative information and who, depending on the structure of the higher education institution, may be the departmental coordinator or works at the international relations office or equivalent body within the institution.

  • Please (a) Issue a check payable to Borrower or

  • Contact Information 1. The contact information of the Programme Operator is as specified in this programme agreement.

  • Contact Persons 12.1 All matters or enquiries regarding this Agreement will be directed to each party’s Contact Person (set out in the Key Details).

Time is Money Join Law Insider Premium to draft better contracts faster.